[Primary soft tissue sarcomas of mediastinum: experience in 22 cases from a single institution].
OBJECTIVE
To assess the presentation, imaging features, and prognostic factors of primary soft tissue sarcoma of mediastinum.


METHODS
The clinical data of 22 patients with primary soft tissue sarcoma of mediastinum, 12 males and 10 females, aged 46 (28-69), hospitalized over 27 years were retrospectively reviewed, focusing on the clinical presentations, preoperative diagnosis, imaging features, immunohistochemical studies, treatment, and survival.


RESULTS
Chest pain, dyspnea, cough, and shoulder pain were the most common complaints. Imaging findings showed large lobulated mass. The overall 5-year survival rate was 62. 8%. The 5-year survival rate of the patients with tumors larger than 10 cm was 65.6%, significantly higher than that of the patients with tumors smaller than 10 cm (38.8% , P = 0. 019). The long-term survival rate of the patients who received complete resection was 84 months , longer, though not significantly, than that of the patients who received incomplete resection (8 months, P = 0.059). The 5-year survival rate of the patients with lesions at high grade and stage III were 38.2% and 38.2% respectively, both lower, though not significantly, than those of lesions at low grade and stage I (60% and 60% respectively, both P =0.317). The 5-year survival rate of the patients who received surgery only was 8 months, shorter, though not significantly, than that of the patients who received surgery plus adjuvant therapy (12 months, P = 0.204).


CONCLUSIONS
Tumor size and character of resection are important prognostic factors for primary soft tissue sarcoma of mediastinum.
Mu
Ju-Wei
JW
Department of Thoracic Surgery, Cancer Hospital, Chinese Academy of Medical Sciences, Beijing 100021, China.
Xing
Xue-Zhong
XZ
Li
Jian
J
Cheng
Gui-Yu
GY
Sun
Ke-Lin
KL
He
Jie
J
D000328:Adult; D000368:Aged; D015703:Antigens, CD / Q000032:analysis; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008479:Mediastinal Neoplasms / Q000175:diagnosis / Q000378:metabolism / Q000601:surgery*; D008482:Mediastinum / Q000473:pathology / Q000601:surgery; D008875:Middle Aged; D012189:Retrospective Studies; D012509:Sarcoma / Q000175:diagnosis / Q000378:metabolism / Q000601:surgery*; D016019:Survival Analysis; D014746:Vimentin / Q000032:analysis; D000097382:CD68 Molecule
D015703:Antigens, CD; D015214:Antigens, Differentiation, Myelomonocytic; D014746:Vimentin; C067980:CD68 antigen, human; D000097382:CD68 Molecule